Cressey T., Van Dyke R., Jourdain Gonzague, Puthanakit T., Roongpisuthipong A., Achalapong J., Yuthavisuthi P., Prommas S., Chotivanich N., Maupin R., Smith E., Shapiro D. E., Mirochnick M. (2009). Early postpartum pharmacokinetics of Lopinavir initiated intrapartum in thai women. Antimicrobial Agents and Chemotherapy, 53 (5), p. 2189-2191. ISSN 0066-4804.
Titre du document
Early postpartum pharmacokinetics of Lopinavir initiated intrapartum in thai women
Année de publication
2009
Auteurs
Cressey T., Van Dyke R., Jourdain Gonzague, Puthanakit T., Roongpisuthipong A., Achalapong J., Yuthavisuthi P., Prommas S., Chotivanich N., Maupin R., Smith E., Shapiro D. E., Mirochnick M.
Source
Antimicrobial Agents and Chemotherapy, 2009,
53 (5), p. 2189-2191 ISSN 0066-4804
Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) mu g.h/ml, 11.2 (8.0 to 17.5) mu g/ml, and 4.6 (1.7 to 12.5) mu g/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
THAILANDE
Localisation
Fonds IRD [F B010089807]
Identifiant IRD
PAR00003512
